These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37747471)

  • 1. Fosfomycin-meropenem synergistic combination against NDM carbapenemase-producing Klebsiella pneumoniae strains.
    Della Rocca MT; Di Caprio G; Colucci F; Merola F; Panetta V; Cordua E; Greco R
    New Microbiol; 2023 Sep; 46(3):264-270. PubMed ID: 37747471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing
    Erturk Sengel B; Altinkanat Gelmez G; Soyletir G; Korten V
    J Chemother; 2020 Sep; 32(5):237-243. PubMed ID: 32228228
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.
    Erdem F; Abulaila A; Aktas Z; Oncul O
    Antimicrob Resist Infect Control; 2020 May; 9(1):70. PubMed ID: 32430058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of fosfomycin-meropenem and fosfomycin-colistin against carbapenem resistant
    Bakthavatchalam YD; Shankar A; Muthuirulandi Sethuvel DP; Asokan K; Kanthan K; Veeraraghavan B
    Future Sci OA; 2020 Feb; 6(4):FSO461. PubMed ID: 32257374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
    Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
    Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the
    Kilic U; Koroglu M; Olmez M; Altindis M
    Microb Drug Resist; 2020 May; ():. PubMed ID: 32401692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
    Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenem-Resistant
    Ramadan RA; Bedawy AM; Negm EM; Hassan TH; Ibrahim DA; ElSheikh SM; Amer RM
    Infect Drug Resist; 2022; 15():3537-3548. PubMed ID: 35833009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains.
    Adaleti R; Nakipoğlu Y; Çalık Ş; Arıcı N; Kansak N; Şenbayrak S; Aksaray S
    Acta Microbiol Immunol Hung; 2023 Jun; 70(2):155-160. PubMed ID: 37133999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.